中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 11
Nov.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(11): 2326-2331

Preventive and therapeutic effects of berberine on liver diseases and its mechanism

DOI: 10.12449/JCH241130
  • 1.

    Clinical Medical College of Guangdong Pharmaceutical University，Guangzhou 510000，China

  • 2.

    Department of Gastroenterology，The Third Affiliated Hospital of Navy Medical University，Shanghai 200438，China

Research funding:

National Natural Science Foundation of China (82003005)

More Information
  • Corresponding author: HU Bing， drhubing@aliyun.com （ORCID： 0000-0003-4167-9038）
  • Received Date: 2024-02-23
  • Accepted Date: 2024-05-10
  • Published Date: 2024-11-25
    Abstract
  • Berberine is an antipyretic and detoxicating drug commonly used in clinical practice， and it is currently used for the routine treatment of gastrointestinal diseases such as bacterial gastroenteritis and diarrhea. However， several recent studies have shown that berberine can exert a therapeutic effect on the diseases such as autoimmune hepatitis， viral hepatitis， nonalcoholic fatty liver disease， and liver cancer by regulating the AMPK and TGF-β pathways and altering the composition of intestinal flora. This provides new drugs for the treatment of these diseases， expands the potential indications of berberine， and provides clues for the follow-up research and development of similar drugs. This article summarizes the therapeutic effect and mechanism of berberine on various liver diseases， in order to provide a reference for effective clinical application.

     

    • FullText(HTML)
  • loading
    • References(42)
  • [1]
    HU CY, MO ZX. Research progress on pharmacological actions and mechanism of berberine[J]. China Ind Econ, 2017, 23( 20): 213- 219. DOI: 10.13422/j.cnki.syfjx.2017200213.

    胡诚毅, 莫志贤. 黄连素的药理作用及机制研究进展[J]. 中国实验方剂学杂志, 2017, 23( 20): 213- 219. DOI: 10.13422/j.cnki.syfjx.2017200213.
    [2]
    WONGBUTDEE J. Physiological effects of berberine[J]. Thai Pharm Health Sci J, 2008( 4): 78- 83.
    [3]
    YAO J, KONG WJ, JIANG JD. Learning from berberine: Treating chronic diseases through multiple targets[J]. Sci China Life Sci, 2015, 58( 9): 854- 859. DOI: 10.1007/s11427-013-4568-z.
    [4]
    SHEN QM. Physiological function of liver[J]. Liver Dr, 2022( 4): 35- 37.

    沈启明. 肝脏的生理功能[J]. 肝博士, 2022( 4): 35- 37.
    [5]
    ZHOU MT, DENG Y, LIU MC, et al. The pharmacological activity of berberine, a review for liver protection[J]. Eur J Pharmacol, 2021, 890: 173655. DOI: 10.1016/j.ejphar.2020.173655.
    [6]
    LAN SH, TANG QY, LI NN, et al. Mechanism of action of Xiaochaihu Decoction in the treatment of hepatitis B based on network pharmacology[J]. J Clin Hepatol, 2021, 37( 10): 2308- 2315. DOI: 10.3969/j.issn.1001-5256.2021.10.010.

    蓝绍航, 唐秋媛, 李娜娜, 等. 基于网络药理学研究小柴胡汤治疗乙型肝炎的作用机制[J]. 临床肝胆病杂志, 2021, 37( 10): 2308- 2315. DOI: 10.3969/j.issn.1001-5256.2021.10.010.
    [7]
    GUO WZ, KANG Z. Old drugs and new drugs are used to treat viral hepatitis[J]. Int Med Health Guid Issues, 2005, 11( 12): 87- 88. DOI: 10.3760/cma.j.issn.1007-1245.2005.12.049.

    郭文征, 康庄. 老药新用治疗病毒性肝炎[J]. 国际医药卫生导报, 2005, 11( 12): 87- 88. DOI: 10.3760/cma.j.issn.1007-1245.2005.12.049.
    [8]
    LI F, LI B, ZHU QY. Research progress on the epidemiological characteristics and diagnosis of hepatitis C in China[J]. Int J Virol, 2023, 30( 6): 509- 511. DOI: 10.3760/cma.j.issn.1673-4092.2023.06.014.

    黎锋, 李博, 朱秋映. 中国丙肝流行特征与诊断研究进展[J]. 国际病毒学杂志, 2023, 30( 6): 509- 511. DOI: 10.3760/cma.j.issn.1673-4092.2023.06.014.
    [9]
    HUNG TC, JASSEY A, LIU CH, et al. Berberine inhibits hepatitis C virus entry by targeting the viral E2 glycoprotein[J]. Phytomedicine, 2019, 53: 62- 69. DOI: 10.1016/j.phymed.2018.09.025.
    [10]
    WANG YY, ZHOU L, LI YN, et al. The effects of berberine on concanavalin A-induced autoimmune hepatitis(AIH) in mice and the adenosine 5'-monophosphate(AMP)-activated protein kinase(AMPK) pathway[J]. Med Sci Monit, 2017, 23: 6150- 6161. DOI: 10.12659/msm.907377.
    [11]
    KOWDLEY KV, FORMAN L, EKSTEEN B, et al. A randomized, dose-finding, proof-of-concept study of berberine ursodeoxycholate in patients with primary sclerosing cholangitis[J]. Am J Gastroenterol, 2022, 117( 11): 1805- 1815. DOI: 10.14309/ajg.0000000000001956.
    [12]
    PHOGAT A, SINGH J, KUMAR V, et al. Berberine mitigates acetamiprid-induced hepatotoxicity and inflammation via regulating endogenous antioxidants and NF-κB/TNF-α signaling in rats[J]. Environ Sci Pollut Res Int, 2023, 30( 37): 87412- 87423. DOI: 10.1007/s11356-023-28279-1.
    [13]
    MAHMOUD AM, HOZAYEN WG, RAMADAN SM. Berberine ameliorates methotrexate-induced liver injury by activating Nrf2/HO-1 pathway and PPARγ, and suppressing oxidative stress and apoptosis in rats[J]. Biomed Pharmacother, 2017, 94: 280- 291. DOI: 10.1016/j.biopha.2017.07.101.
    [14]
    KOPERSKA A, WESOŁEK A, MOSZAK M, et al. Berberine in non-alcoholic fatty liver disease-a review[J]. Nutrients, 2022, 14( 17): 3459. DOI: 10.3390/nu14173459.
    [15]
    WANG CE, XU WT, GONG J, et al. Research progress in the treatment of nonalcoholic fatty liver disease[J]. Clin J Med Offic, 2022, 50( 9): 897- 899, 903. DOI: 10.16680/j.1671-3826.2022.09.06.

    王彩娥, 许文涛, 宫建, 等. 非酒精性脂肪性肝病治疗研究进展[J]. 临床军医杂志, 2022, 50( 9): 897- 899, 903. DOI: 10.16680/j.1671-3826.2022.09.06.
    [16]
    ZHU XP, BIAN H, WANG L, et al. Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway[J]. Free Radic Biol Med, 2019, 141: 192- 204. DOI: 10.1016/j.freeradbiomed.2019.06.019.
    [17]
    WANG P, LI RK, LI YQ, et al. Berberine alleviates non-alcoholic hepatic steatosis partially by promoting SIRT1 deacetylation of CPT1A in mice[J]. Gastroenterol Rep, 2023, 11: goad032. DOI: 10.1093/gastro/goad032.
    [18]
    SUN YX, XIA MF, YAN HM, et al. Berberine attenuates hepatic steatosis and enhances energy expenditure in mice by inducing autophagy and fibroblast growth factor 21[J]. Br J Pharmacol, 2018, 175( 2): 374- 387. DOI: 10.1111/bph.14079.
    [19]
    ZHU L, XU JJ, LI HD, et al. Berberine ameliorates abnormal lipid metabolism via the adenosine monophosphate-activated protein kinase/sirtuin 1 pathway in alcohol-related liver disease[J]. Lab Invest, 2023, 103( 4): 100041. DOI: 10.1016/j.labinv.2022.100041.
    [20]
    CHEN Y, LI Q, ZHAO SW, et al. Berberine protects mice against type 2 diabetes by promoting PPARγ-FGF21-GLUT2-regulated insulin sensitivity and glucose/lipid homeostasis[J]. Biochem Pharmacol, 2023, 218: 115928. DOI: 10.1016/j.bcp.2023.115928.
    [21]
    KHATER SI, ALMANAA TN, FATTAH DMA, et al. Liposome-encapsulated berberine alleviates liver injury in type 2 diabetes via promoting AMPK/mTOR-mediated autophagy and reducing ER stress: Morphometric and immunohistochemical scoring[J]. Antioxidants, 2023, 12( 6): 1220. DOI: 10.3390/antiox12061220.
    [22]
    CAI YJ, YANG QN, YU YQ, et al. Efficacy and underlying mechanisms of berberine against lipid metabolic diseases: A review[J]. Front Pharmacol, 2023, 14: 1283784. DOI: 10.3389/fphar.2023.1283784.
    [23]
    YUAN XL, WANG J, TANG XY, et al. Berberine ameliorates nonalcoholic fatty liver disease by a global modulation of hepatic mRNA and lncRNA expression profiles[J]. J Transl Med, 2015, 13: 24. DOI: 10.1186/s12967-015-0383-6.
    [24]
    DAI L, LU S, SHEN TB, et al. Methyltransferase SETD2 mediates hepatoprotection of berberine against steatosis[J]. Ann Transl Med, 2022, 10( 10): 552. DOI: 10.21037/atm-22-1753.
    [25]
    YANG FJ, GAO RM, LUO XX, et al. Berberine influences multiple diseases by modifying gut microbiota[J]. Front Nutr, 2023, 10: 1187718. DOI: 10.3389/fnut.2023.1187718.
    [26]
    ZHANG YY, YAN JJ, ZHANG P, et al. Berberine maintains gut microbiota homeostasis and ameliorates liver inflammation in experimental non-alcoholic fatty liver disease[J]. Chin J Gastroenterol, 2018, 23( 4): 209- 215. DOI: 10.3969/j.issn.1008-7125.2018.04.004.

    张园园, 严君君, 张培, 等. 黄连素调节肠道菌群减轻非酒精性脂肪性肝病肝脏炎症的实验研究[J]. 胃肠病学, 2018, 23( 4): 209- 215. DOI: 10.3969/j.issn.1008-7125.2018.04.004.
    [27]
    GUO HH, SHEN HR, WANG LL, et al. Berberine is a potential alternative for metformin with good regulatory effect on lipids in treating metabolic diseases[J]. Biomed Pharmacother, 2023, 163: 114754. DOI: 10.1016/j.biopha.2023.114754.
    [28]
    WANG C, YANG YT, CHEN JY, et al. Berberine protects against high-energy and low-protein diet-induced hepatic steatosis: Modulation of gut microbiota and bile acid metabolism in laying hens[J]. Int J Mol Sci, 2023, 24( 24): 17304. DOI: 10.3390/ijms242417304.
    [29]
    YI JZ, WU SY, TAN SW, et al. Berberine alleviates liver fibrosis through inducing ferrous redox to activate ROS-mediated hepatic stellate cells ferroptosis[J]. Cell Death Discov, 2021, 7( 1): 374. DOI: 10.1038/s41420-021-00768-7.
    [30]
    LI J, PAN Y, KAN MJ, et al. Hepatoprotective effects of berberine on liver fibrosis via activation of AMP-activated protein kinase[J]. Life Sci, 2014, 98( 1): 24- 30. DOI: 10.1016/j.lfs.2013.12.211.
    [31]
    LIU XZ, WANG LF, TAN SW, et al. Therapeutic effects of berberine on liver fibrosis are associated with lipid metabolism and intestinal flora[J]. Front Pharmacol, 2022, 13: 814871. DOI: 10.3389/fphar.2022.814871.
    [32]
    XIE ZP, ZHOU Y, LIN M, et al. Binding of berberine to PEBP1 synergizes with sorafenib to induce the ferroptosis of hepatic stellate cells[J]. Amino Acids, 2023, 55( 12): 1867- 1878. DOI: 10.1007/s00726-023-03345-7.
    [33]
    DOU Q, LI Y, WANG YY, et al. Effect of berberine on protecting liver function and inhibiting inflammation in cirrhotic rats[j]. J Guangzhou Univ Tradit Chin Med, 2021, 38( 12): 2708- 2715. DOI: 10.13359/j.cnki.gzxbtcm.2021.12.027.

    窦芊, 李赢, 王园园, 等. 小檗碱对肝硬化大鼠肝功能的保护及炎症抑制作用[J]. 广州中医药大学学报, 2021, 38( 12): 2708- 2715. DOI: 10.13359/j.cnki.gzxbtcm.2021.12.027.
    [34]
    WANG N, FENG YB, ZHU MF, et al. Berberine induces autophagic cell death and mitochondrial apoptosis in liver cancer cells: The cellular mechanism[J]. J Cell Biochem, 2010, 111( 6): 1426- 1436. DOI: 10.1002/jcb.22869.
    [35]
    REN G, GUO JH, FENG CL, et al. Berberine inhibits carcinogenesis through antagonizing the ATX-LPA-LPAR2-p38-leptin axis in a mouse hepatoma model[J]. Mol Ther Oncolytics, 2022, 26: 372- 386. DOI: 10.1016/j.omto.2022.08.001.
    [36]
    GUO W, TAN HY, LI S, et al. Glutamic-pyruvic transaminase 1 facilitates alternative fuels for hepatocellular carcinoma growth-a small molecule inhibitor, berberine[J]. Cancers, 2020, 12( 7): 1854. DOI: 10.3390/cancers12071854.
    [37]
    ZHENG HL. Inhibitory effect of berberine on hepatocellular carcinoma metastasis and its mechanism by suppressing the‘phoenix rising’pathway[D]. Changchun: Jilin University, 2016.

    郑慧琳. 黄连素对“凤凰涅槃”信号通路引起肝癌转移的抑制作用及机制探讨[D]. 长春: 吉林大学, 2016.
    [38]
    DU HY, GU JY, PENG Q, et al. Berberine suppresses EMT in liver and gastric carcinoma cells through combination with TGFβR regulating TGF-β/smad pathway[J]. Oxid Med Cell Longev, 2021, 2021: 2337818. DOI: 10.1155/2021/2337818.
    [39]
    SHOU JW, SHAW PC. Berberine activates PPARδ and promotes gut microbiota-derived butyric acid to suppress hepatocellular carcinoma[J]. Phytomedicine, 2023, 115: 154842. DOI: 10.1016/j.phymed.2023.154842.
    [40]
    LIN YB, SHENG MW, WENG YQ, et al. Berberine protects against ischemia/reperfusion injury after orthotopic liver transplantation via activating Sirt1/FoxO3α induced autophagy[J]. Biochem Biophys Res Commun, 2017, 483( 2): 885- 891. DOI: 10.1016/j.bbrc.2017.01.028.
    [41]
    GENDY AM, ELNAGAR MR, ALLAM MM, et al. Berberine-loaded nanostructured lipid carriers mitigate warm hepatic ischemia/reperfusion-induced lesion through modulation of HMGB1/TLR4/NF-κB signaling and autophagy[J]. Biomed Pharmacother, 2022, 145: 112122. DOI: 10.1016/j.biopha.2021.112122.
    [42]
    SHENG M, ZHOU Y, YU W, et al. Protective effect of Berberine pretreatment in hepatic ischemia/reperfusion injury of rat[J]. Transplant Proc, 2015, 47( 2): 275- 282. DOI: 10.1016/j.transproceed.2015.01.010.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (120) PDF downloads(24) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return